PART I Item 1. B usiness. Company Overview We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity. Our approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clin...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-06 | 2025-12-31 | 0001193125-26-096550 | EDGAR | 96K words |
| 2025-03-27 | 2024-12-31 | 0001558370-25-003750 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001798749-24-000015 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001798749-23-000015 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001493152-22-008189 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281525 | EDGAR | 62K words |
| 2025-08-13 | 2025-06-30 | 0001193125-25-179853 | EDGAR | — |
| 2025-04-25 | 2025-03-31 | 0001558370-25-005564 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001798749-24-000059 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001798749-24-000049 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007985 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001798749-23-000060 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001798749-23-000056 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001798749-23-000039 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017586 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022598 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013523 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-140091 | EDGAR | 1K words |
| 2026-03-06 | 0001193125-26-094967 | EDGAR | — |
| 2026-01-05 | 0001193125-26-001502 | EDGAR | — |
| 2025-12-15 | 0001193125-25-318436 | EDGAR | — |
| 2025-11-14 | 0001193125-25-281498 | EDGAR | — |
| 2025-10-07 | 0001193125-25-232562 | EDGAR | — |
| 2025-09-09 | 0001193125-25-198777 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179828 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153427 | EDGAR | — |
| 2025-05-14 | 0001193125-25-119856 | EDGAR | — |
82 total filings indexed. 55 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001798749 |
| Ticker | JBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.jadebiosciences.com |
| Listed | 2025-04-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report